	US 12,071,402 B2
	Immunosuppressant formulations
Philippe Michel Rene Bouillot, Basel (CH); and Emeric Reynaud, Village Neuf (FR)
Assigned to NOVARTIS AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Apr. 14, 2021, as Appl. No. 17/230,175.
Application 17/230,175 is a continuation of application No. 16/804,926, filed on Feb. 28, 2020, abandoned.
Application 16/804,926 is a continuation of application No. 13/917,730, filed on Jun. 14, 2013, abandoned.
Application 13/917,730 is a continuation in part of application No. PCT/EP2012/050151, filed on Jan. 5, 2012.
Claims priority of application No. 11150431 (EP), filed on Jan. 7, 2011.
Prior Publication US 2022/0064110 A1, Mar. 3, 2022
Int. Cl. C07D 205/04 (2006.01); A61K 9/20 (2006.01); A61K 31/397 (2006.01)

CPC C07D 205/04 (2013.01) [A61K 9/2004 (2013.01); A61K 31/397 (2013.01)]

12 Claims

1. A solid phase pharmaceutical composition comprising

one or more pharmaceutically acceptable non-basic excipients and 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid or a pharmacologically acceptable salt thereof, wherein at least one of the one or more pharmaceutically acceptable non-basic excipients is glyceryl behenate, and wherein the solid phase pharmaceutical composition does not comprise magnesium stearate.